Cargando…

In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry

INTRODUCTION: (177)Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of (177)Lu-OPS201 in animals and humans. METHODS: Data on biokinetics of (17...

Descripción completa

Detalles Bibliográficos
Autores principales: Beykan, Seval, Fani, Melpomeni, Jensen, Svend Borup, Nicolas, Guillaume, Wild, Damian, Kaufmann, Jens, Lassmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348830/
https://www.ncbi.nlm.nih.gov/pubmed/30733648
http://dx.doi.org/10.1155/2019/6438196
_version_ 1783390176213467136
author Beykan, Seval
Fani, Melpomeni
Jensen, Svend Borup
Nicolas, Guillaume
Wild, Damian
Kaufmann, Jens
Lassmann, Michael
author_facet Beykan, Seval
Fani, Melpomeni
Jensen, Svend Borup
Nicolas, Guillaume
Wild, Damian
Kaufmann, Jens
Lassmann, Michael
author_sort Beykan, Seval
collection PubMed
description INTRODUCTION: (177)Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of (177)Lu-OPS201 in animals and humans. METHODS: Data on biokinetics of (177)Lu-OPS201 were analyzed in athymic nude Foxn1 (nu) mice (28 F, weight: 26 ± 1 g), Danish Landrace pigs (3 F-1 M, weight: 28 ± 2 kg), and patients (3 F-1 M, weight: 61 ± 17 kg) with administered activities of 0.19–0.27 MBq (mice), 97–113 MBq (pigs), and 850–1086 MBq (patients). After euthanizing mice (up to 168 h), the organ-specific activity contents (including blood) were measured. Multiple planar and SPECT/CT scans were performed until 250 h (pigs) and 72 h (patients) to quantify the uptake in the kidneys and liver. Blood samples were taken up to 23 h (patients) and 300 h (pigs). In pigs and patients, kidney protection was applied. Time-dependent uptake data sets were created for each species and organ/tissue. Biexponential fits were applied to compare the biokinetics in the kidneys, liver, and blood of each species. The time-integrated activity coefficients (TIACs) were calculated by using NUKFIT. To determine the optimal scaling, several methods (relative mass scaling, time scaling, combined mass and time scaling, and allometric scaling) were compared. RESULTS: A fast blood clearance of the compound was observed in the first phase (<56 h) for all species. In comparison with patients, pigs showed higher liver retention. Based on the direct comparison of the TIACs, an underestimation in mice (liver and kidneys) and an overestimation in pigs' kidneys compared to the patient data (kidney TIAC: mice = 1.4 h, pigs = 7.7 h, and patients = 5.8 h; liver TIAC: mice = 0.7 h, pigs = 4.1 h, and patients = 5.3 h) were observed. Most similar TIACs were obtained by applying time scaling (mice) and combined scaling (pigs) (kidney TIAC: mice = 3.9 h, pigs = 4.8 h, and patients = 5.8 h; liver TIAC: mice = 0.9 h, pigs = 4.7 h, and patients = 5.3 h). CONCLUSION: If the organ mass ratios between the species are high, the combined mass and time scaling method is optimal to minimize the interspecies differences. The analysis of the fit functions and the TIACs shows that pigs are better mimicking human biokinetics.
format Online
Article
Text
id pubmed-6348830
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63488302019-02-07 In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry Beykan, Seval Fani, Melpomeni Jensen, Svend Borup Nicolas, Guillaume Wild, Damian Kaufmann, Jens Lassmann, Michael Contrast Media Mol Imaging Research Article INTRODUCTION: (177)Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of (177)Lu-OPS201 in animals and humans. METHODS: Data on biokinetics of (177)Lu-OPS201 were analyzed in athymic nude Foxn1 (nu) mice (28 F, weight: 26 ± 1 g), Danish Landrace pigs (3 F-1 M, weight: 28 ± 2 kg), and patients (3 F-1 M, weight: 61 ± 17 kg) with administered activities of 0.19–0.27 MBq (mice), 97–113 MBq (pigs), and 850–1086 MBq (patients). After euthanizing mice (up to 168 h), the organ-specific activity contents (including blood) were measured. Multiple planar and SPECT/CT scans were performed until 250 h (pigs) and 72 h (patients) to quantify the uptake in the kidneys and liver. Blood samples were taken up to 23 h (patients) and 300 h (pigs). In pigs and patients, kidney protection was applied. Time-dependent uptake data sets were created for each species and organ/tissue. Biexponential fits were applied to compare the biokinetics in the kidneys, liver, and blood of each species. The time-integrated activity coefficients (TIACs) were calculated by using NUKFIT. To determine the optimal scaling, several methods (relative mass scaling, time scaling, combined mass and time scaling, and allometric scaling) were compared. RESULTS: A fast blood clearance of the compound was observed in the first phase (<56 h) for all species. In comparison with patients, pigs showed higher liver retention. Based on the direct comparison of the TIACs, an underestimation in mice (liver and kidneys) and an overestimation in pigs' kidneys compared to the patient data (kidney TIAC: mice = 1.4 h, pigs = 7.7 h, and patients = 5.8 h; liver TIAC: mice = 0.7 h, pigs = 4.1 h, and patients = 5.3 h) were observed. Most similar TIACs were obtained by applying time scaling (mice) and combined scaling (pigs) (kidney TIAC: mice = 3.9 h, pigs = 4.8 h, and patients = 5.8 h; liver TIAC: mice = 0.9 h, pigs = 4.7 h, and patients = 5.3 h). CONCLUSION: If the organ mass ratios between the species are high, the combined mass and time scaling method is optimal to minimize the interspecies differences. The analysis of the fit functions and the TIACs shows that pigs are better mimicking human biokinetics. Hindawi 2019-01-03 /pmc/articles/PMC6348830/ /pubmed/30733648 http://dx.doi.org/10.1155/2019/6438196 Text en Copyright © 2019 Seval Beykan et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Beykan, Seval
Fani, Melpomeni
Jensen, Svend Borup
Nicolas, Guillaume
Wild, Damian
Kaufmann, Jens
Lassmann, Michael
In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
title In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
title_full In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
title_fullStr In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
title_full_unstemmed In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
title_short In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
title_sort in vivo biokinetics of (177)lu-ops201 in mice and pigs as a model for predicting human dosimetry
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348830/
https://www.ncbi.nlm.nih.gov/pubmed/30733648
http://dx.doi.org/10.1155/2019/6438196
work_keys_str_mv AT beykanseval invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry
AT fanimelpomeni invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry
AT jensensvendborup invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry
AT nicolasguillaume invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry
AT wilddamian invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry
AT kaufmannjens invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry
AT lassmannmichael invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry